Pediatric Neurology
Volume 25, Issue 1 , Pages 21-29 , July 2001

Lafora’s disease: towards a clinical, pathologic, and molecular synthesis

  • Berge A Minassian, MD

      Affiliations

    • Division of Neurology; Department of Paediatrics and Department of Genetics; The Hospital for Sick Children and The University of Toronto; Toronto, Ontario, M5G 1X8, Canada
    • Corresponding Author InformationCommunications should be addressed to: Dr. Minassian; Division of Neurology; Department of Paediatrics and Department of Genetics; The Hospital for Sick Children and The University of Toronto; 555 University Ave., Toronto, Ontario, M5G 1X8, Canada

Received 29 June 2000 ,Accepted 11 December 2000.

References 

  1. Hauser WA. Incidence and prevalence. In:  Engel J,  Pedley TA editor. Epilepsy, a comprehensive textbook. Philadelphia: Lippincott-Raven; 1997;p. 47–57
  2. Roger J, Genton P, Bureau M, Dravet C. Progressive myoclonus epilepsies in childhood and adolescence. In:  Roger J,  Bureau M,  Dravet C,  Dreifuss FE,  Perret A,  Wolf P editor. Epileptic syndromes in infancy, childhood and adolescence. 2nd ed.. London: Libbey; 1992;p. 381–400
  3. Goebel HH. The Neuronal ceroid-lipofuscinoses. J Child Neurol. 1995;10:424–437
  4. Mole SE. Batten’s disease (Eight genes and still counting?). Lancet. 1999;354:443–445
  5. Lehesjoki A-E, Koskiniemi M. Progressive myoclonus epilepsy of Unverricht-Lundborg type. Epilepsia. 1999;40(Suppl 3):23–28
  6. Cock H, Schapira AHV. Mitochondrial DNA mutations and mitochondrial dysfunction in epilepsy. Epilepsia. 1999;40(Suppl 3):33–40
  7. Minassian BA, Sainz J, Delgado-Escueta AV. Genetics of myoclonic and myoclonus epilepsies. Clin Neurosci 1996:223-35.
  8. Schwarz G, Yanoff M. Lafora’s Disease. Arch Neurol. 1965;12:173–188
  9. Janeway R, Ravens J, Rupert P, Larry A, Odor L, Suzuki K. Progressive Myoclonus Epilepsy with Lafora Inclusion bodies. Arch Neurol. 1967;16:565–582
  10. Gambetti P, Di Mauro S, Hirt L, Blume RP. Myoclonic epilepsy with Lafora bodies. Arch Neurol. 1971;25:483–493
  11. Neville HE, Brooke MH, Austin JH. Studies in Myoclonus epilepsy (Lafora Body form). Arch Neurol. 1974;30:466–474
  12. Carpenter S, Karpati G, Andermann F, Jacob JC, Andermann E. Lafora’s disease (Peroxisomal storage in skeletal muscle). Neurology. 1974;24:531–538
  13. Van Heycop Ten Ham MW. Lafora disease, a form of progressive myoclonus epilepsy. Handbook Clini Neurol. 1974;15:382–422
  14. Busard HL, Renier WO, Gabreels FJ, et al.  Lafora disease (a quantitative morphological and biochemical study of the cerebral cortex). Clin Neuropathol. 1987;6:1–6
  15. Nishimura RN, Ishak KG, Reddick R, Porter R, James S, Barranger JA. Lafora Disease (Diagnosis by liver biopsy). Ann Neurol. 1980;8:409–415
  16. Kobayashi K, Iyoda K, Ohtsuka Y, Ohtahara S, Yamada M. Longitudinal clinicoelectrophysiologic study of a case of lafora disease proven by skin biopsy. Epilepsia. 1990;31:194–201
  17. Baumann RJ, Kocoshis SA, Wilson S. Lafora Disease (Liver histopathology in presymptomatic children). Ann Neurol. 1983;4:86–89
  18. Roger J, Pellissier JF, Bureau M, Dravet C, Revol M, Tinuper P. Le diagnostic precoce de la maladie de Lafora. Importance des manifestations paroxystiques visuelles et interet de la biopsie cutanee. Rev Neurol (Paris). 1983;139:115–124
  19. Busard BLSM, Renier WO, Gabreels FJM, Jaspar HHJ, van Haelst UJG, Stooff JL. Lafora’s Disease. Arch Neurol. 1986;43:296–299
  20. Drury I, Blaivas M, Abou-Khalil B, Beydoun A. Biopsy results in a kindred with Lafora Disease. Arch Neurol. 1993;50:102–105
  21. Berkovic SF, Cochius J, Andermann E, Andermann F. Progressive myoclonus epilepsies (Clinical and genetic aspects). Epilepsia. 1993;34(Suppl 3):S19–S30
  22. Acharya JN, Satishchandra P, Shankar SK. Familial progressive myoclonus epilepsy (Clinical and electrophysiologic observations). Epilepsia. 1995;36:429–434
  23. Minassian BA, Ianzano L, Meloche M, et al.  Mutation spectrum and predicted function of laforin in Lafora’s progressive myoclonus epilepsy. Neurology. 2000;55:341–346
  24. Oksel F, Tekgul H, Genc S, Ozyurek R, Akalin T, Tututuncuoglu S. A case of Lafora’s disease associated with cardiac arrhythmia. J Child Neurol. 1999;14:745–746
  25. Roger J, Gastaut H, Boudouresques J, Toga M, Dubois D, Lob H. Epilepsie-myoclonie progressive avec corps de Lafora. Etude clinique et polygraphique. Controle anatomique ultra-structural. Rev Neurol (Paris). 1967;116:197–212
  26. Shibasaki H, Neshige R. Photic cortical reflex myoclonus. Ann Neurol. 1987;22:252–257
  27. Rubboli G, Meletti S, Gardella E, et al.  Photic reflex myoclonus (A neurophysiologic study in progressive myoclonus epilepsy). Epilepsia. 1999;40(Suppl 4):50–58
  28. Lafora GR, Gluck B. Beitrag zur histopathologie der myoklonischen epilepsie. Z Ges Neurol Psychiat. 1911;6:1–14
  29. Cavanagh JB. Corpora-amylacea and the family of polyglucosan diseases. Brain Res Rev. 1999;29:265–295
  30. Harriman DGF, Millar JHD. Progressive familial myoclonic epilepsy in three families (Its clinical features and pathological basis). Brain. 1955;78:325–349
  31. Carpenter S, Karpati G. Sweat gland duct cells in Lafora disease (Diagnosis by skin biopsy). Neurology. 1981;31:1564–1568
  32. Busard HLSM, Gobreels-Festen AAWM, Renih WU, Gabreels FJ, Stadhouders AM. Axilla skin biopsy; a reliable test for the diagnosis of Lafora’s disease. Ann Neurol. 1987;21:599–601
  33. Minassian BA, Ianzano L, Delgado-Escueta AV, Scherer SW. New deletion mutations in EPM2A and the genetic diagnosis of Lafora’s disease. Neurol. 2000;54:488–490
  34. Sakai M, Austin J, Witmer F, Trueb L. Studies in myoclonus epilepsy (Lafora body form); II. Polyglucosans in the systemic deposits of myoclonus epilepsy and in corpora amylacea. Neurology. 1970;20:160–176
  35. Nikaido T, Austin J, Stukenbrok H. Studies in myoclonus epilepsy. III. The effects of amylolytic enzymes on the ultrastructure of Lafora bodies. J Histochem Cytochem. 1971;19:382–385
  36. Schochet SS, McCormick WF, Zellweger H. Type IV glycogenosis (amylopectinosis) (Light and electron microscopic observations). Arch Pathol. 1970;90:354–363
  37. Robitaille Y, Carpenter S, Karpati G, DiMauro S. A distinct form of adult polyglucosan body disease with massive involvement of central and peripheral neuronal processes and astrocytes. A report of four cases and a review of the occurrence of polyglucosan bodies in other conditions such as Lafora’s disease and normal aging. Brain. 1980;103:315–336
  38. Thon VJ, Khalil M, Cannon JF. Isolation of human glycogen branching enzyme cDNAs by screening complementation in yeast. J Biol Chem. 1993;268:7509–7513
  39. Lossos A, Meiner Z, Barash V, et al.  Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene. Ann Neurol. 1998;44:867–872
  40. Ziemssen F, Sindern E, Schroder JM, et al.  Novel missense mutations in the glycogen-branching enzyme gene in adult polyglucosan body disease. Ann Neurol. 2000;47:536–540
  41. Carpenter S, Karpati G. Ultrastructural findings in Lafora disease. Ann Neurol. 1981;10:63–64
  42. Serratosa JM, Delgado-Escueta AV, Posada I, et al.  The gene for progressive myoclonus epilepsy of the Lafora type maps to chromosome 6q. Hum Mol Genet. 1995;4:1657–1663
  43. Minassian BA, Sainz J, Serratosa JM, et al.  Genetic locus heterogeneity in Lafora’s progressive myoclonus epilepsy. Ann Neurol. 1999;45:262–265
  44. Minassian BA, Lee JR, Herbrick JA, et al.  Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet. 1998;20:171–174
  45. Serratosa JM, Gomez-Garre P, Gallardo ME, et al.  A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). Hum Mol Genet. 1999;8:345–352
  46. Ganesh S, Shoda K, Amano K, et al.  The human and mouse homologues of the epilepsy gene, EPM2A (Isolation and characterization of full-length transcripts and mutation detection in Lafora disease families). Am J Hum Genet. 1999;65:A297
  47. Ganesh S, Shoda K, Delgado-Escueta AV, Yamakawa K. Evolutionary conservation and differential expression of EPM2A gene. Am J Hum Genet. 2000;67:A940
  48. Gomez-Garre P, Sanz Y, Rodriguez de Cordoba S, Serratosa JM. Mutation and polymorphism in the human EPM2 gene in Lafora disease. Am J Hum Genet. 1999;65:A298
  49. Ganesh S, Agarwala KL, Ueda K, et al.  Laforin, defective in the progressive myoclonus epilepsy of lafora type, is a dual-specificity phosphatase associated with polyribosomes. Hum Mol Genet. 2000;9:2251–2261
  50. Minassian BA, Ianzano L, Andrade D, et al.  Laforin in Lafora’s progressive myoclous epilepsy (Function and subcellular localization). Am J Hum Genet. 2000;67:A946
  51. Minassian BA, Andrade D, Ianzano L, et al.  Laforin is a cell membrane and endoplasmic reticulum associated protein tyrosine phosphatase. Ann Neurol. 2001;49:271–276
  52. Tonks NK, Neel BG. From form to function (Signaling by protein tyrosine phosphatases). Cell. 1996;87:365–368
  53. Martell KJ, Angelotti T, Ullrich A. The “VH1-like” dual-specificity protein tyrosine phosphatases. Mol Cells. 1998;8:2–11
  54. Sun H, Lesche R, Li DM, et al.  PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-triphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA. 1999;96:6199–6204
  55. Deshpande T, Takagi T, Hao L, Buratowski S, Charbonneau H. Human PIR1 of the protein-tyrosine phosphatase superfamily has RNA 5′-triphosphatase and diphosphatase activities. J Biol Chem. 1999;274:16590–16594
  56. Henrissat B, Bairoch A. Updating the sequence-based classification of glycosyl hydrolases. Biochem J. 1996;316:695–696
  57. Hengstenberg W, Kohlbrecher D, Witt E, Kruse R, et al.  Structure and function of proteins of the phosphotransferase system and of 6-phospho-beta-glycosidases in gram-positive bacteria. FEMS Microbiol Rev. 1993;12:149–163
  58. Belshaw NJ, Williamson G. Specificity of the binding domain of glucoamylase 1. Eur J Biochem. 1993;211:717–724
  59. Iefuji H, Chino M, Kato M, Iimura Y. Raw-starch-digesting and thermostable α-amylase from the yeast cryptococcus sp. S-2 (Purification, characterization, cloning and sequencing). Biochem J. 1996;318:989–996
  60. Sakai M, Austin J, Witmer F, Trueb L. Studies of corpora amylacea (I. Isolation and preliminary characterization by chemical and histochemical techniques). Arch Neurol. 1969;21:526–544
  61. Yokota T, Ishihara T, Yoshida H, Takahashi M, Uchino F, Hamanaka S. Monoclonal antibody against polyglucosan isolated from the myocardium of a patient with Lafora disease. J Neuropathol Exp Neurol. 1988;47:572–577
  62. Raben N, Danon M, Lu N, et al.  Surprises of genetic engineering (A possible model of polyglucosan body (Lafora) disease). Neurol. 2000;54(Suppl 3):A359–A360
  63. Powell HC, Ward HW, Garrett RS, Orloff MJ, Lampert PW. Glycogen accumulation in the nerves and kidney of chronically diabetic rats. J Neuropathol Exp Neurol. 1979;38:114–127
  64. Chen YT, Burchell A. Glycogen storage diseases. In:  Scriver CR,  Beaudet AL,  Sly WS,  Valle D editor. The metabolic and molecular bases of inherited disease. 7th ed.. New York: McGraw-Hill; 1995;p. 935–965
  65. Angenstein F, Greenough WT, Weiler IJ. Metabotropic glutamate receptor-initiated translocation of protein kinase p90rsk to polyribosomes (A possible factor regulating synaptic protein synthesis). Proc Natl Acad Sci USA. 1998;95:15078–15083
  66. Cajal RYS, Blanes A, Martinez A, Saenz E, Gutierrez M. Lafora’s disease (An ultrastructural and histochemical study). Acta Neuropathologica Berlin. 1975;30:189–196
  67. Hafen E. Kinases and phosphatases—A marriage is consummated. Science. 1998;280:1212–1213

PII: S0887-8994(00)00276-9

Pediatric Neurology
Volume 25, Issue 1 , Pages 21-29 , July 2001

Article Tools

* Image Usage & Resolution